The status quo and influencing factors of renal impairment in the Uyghur population in southern Xinjiang

GUO Xiaoqing; SHAO Yinbao; GUO Heng; GUO Shuxia; HE Jia; LI Yu; MA Rulin

doi:10.16462/j.cnki.zhjbkz.2023.07.010

Volume 27 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(7): 800-806

GUO Xiaoqing, SHAO Yinbao, GUO Heng, GUO Shuxia, HE Jia, LI Yu, MA Rulin. The status quo and influencing factors of renal impairment in the Uyghur population in southern Xinjiang[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(7): 800-806. doi: 10.16462/j.cnki.zhjbkz.2023.07.010

Citation:

GUO Xiaoqing, SHAO Yinbao, GUO Heng, GUO Shuxia, HE Jia, LI Yu, MA Rulin. The status quo and influencing factors of renal impairment in the Uyghur population in southern Xinjiang[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(7): 800-806. doi: 10.16462/j.cnki.zhjbkz.2023.07.010

Citation:

GUO Xiaoqing, SHAO Yinbao, GUO Heng, GUO Shuxia, HE Jia, LI Yu, MA Rulin. The status quo and influencing factors of renal impairment in the Uyghur population in southern Xinjiang[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(7): 800-806. doi: 10.16462/j.cnki.zhjbkz.2023.07.010

PDF( 851 KB)

The status quo and influencing factors of renal impairment in the Uyghur population in southern Xinjiang

doi: 10.16462/j.cnki.zhjbkz.2023.07.010

Department of Preventive Medicine, School of Medicine, Shihezi University, Shihezi 832000, China

Funds:

Xinjiang Construction Corps Financial Science and Technology 2021AB030

More Information

Corresponding author: MA Rulin, E-mail: marulin@shzu.edu.cn
Received Date: 2022-05-29
Rev Recd Date: 2022-08-03

Available Online: 2023-08-08

Publish Date: 2023-07-10

Abstract

Abstract

Objective To analyze the current status of estimated renal impairment in the Uygur population in southern Xinjiang and explore its influencing factors, in order to provide evidence for the early detection and prevention of chronic kidney disease. Methods A total of 11 782 Uyghurs over the age of 18 in the 51st Regiment of the Third Division of the Xinjiang Construction Corps in 2016 were selected as the survey subjects, and the data of a questionnaire survey, physical examination, and laboratory testing were used for analysis. The degree of renal injury distribution was described by the χ ² test and nonparametric test. The ordinal multi-class logistic regression model was used to explore the influencing factors of renal function injury. Results Among the Uyghur population in southern Xinjiang, 20.7% had renal impairment, of which 19.5% had a mild renal impairment and 1.1% had moderate to severe renal impairment. There were significant differences in gender (χ ²=-14.871, P < 0.001), age (χ ²=884.842, P < 0.001), waist-to-height ratio (χ ²=-12.088, P < 0.001), uric acid (UA) (χ ²=-9.006, P < 0.001), fasting blood glucose (FBG) (χ ²=-7.156, P < 0.001), dyslipidemia (χ ²=-9.992, P < 0.001), hypertension (χ ²=-13.706, P < 0.001), cardiovascular disease (CVD) history (χ ²=-8.316, P < 0.001), CVD family history (χ ²=-2.490, P=0.013), and salt addiction (χ ²=-2.373, P=0.018). Being female (OR=2.373, 95% CI: 2.144-2.627, P < 0.001), of advanced age (OR=95.081, 95% CI: 63.375-142.651, P < 0.001), having hyperuricemia (OR=2.277, 95% CI: 1.726-3.004, P < 0.001), dyslipidemia (OR=1.358, 95% CI: 1.222-1.508, P < 0.001), and family history of CVD (OR=1.302, 95% CI: 1.072-1.580, P=0.008) were factors that aggravated the degree of renal damage. Conclusions In the Uyghur population in southern Xinjiang, being female, of advanced age, having hyperlipidemia, dyslipidemia, and a family history of CVD are influencing factors of renal impairment, which aggravated renal impairment. It is recommended to carry out health education and peer education for key groups to improve the awareness rate, treatment rate, and control rate of chronic kidney disease in this group.
- Uygur,
- Estimated glomerular filtration rate,
- Influencing factors

FullText(HTML)

References(16)

References

[1]	Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225): 709-733. DOI: 10.1016/S0140-6736(20)30045-3.
[2]	Curtis S, Komenda P. Screening for chronic kidney disease: moving toward more sustainable health care[J]. Curr Opin Nephrol Hypertens, 2020, 29(3): 333-338. DOI: 10.1097/MNH.000000000000000597.
[3]	Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Ann Intern Med, 2003, 139(2): 137-147. DOI: 10.7326/0003-4819-139-2-200307150-00013.
[4]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心血管病预防指南[J]. 中华健康管理学杂志, 2011, 5(5): 263-279. DOI: 10.3760/cma.j.issn.1674-0815.2011.05.003. Cardiovascular Branch of Chinese Medical Association, Editorial Board of the Chinese Journal of Cardiovascular Diseases. Guidelines for the prevention of cardiovascular diseases in China[J]. Chin J Health Manage, 2011, 5(5): 263-279. DOI: 10.3760/cma.j.issn.1674-0815.2011.05.003.
[5]	Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612. DOI: 10.7326/0003-4819-150-9-200905050-00006.
[6]	Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. DOI: 10.1016/j.kint.2021.05.021.
[7]	中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志, 2020, 36(1): 1-13. DOI: 10.3760/cma.j.issn.1000-6699.2020.01.001. Chinese Society of Endocrinology Chinese Medical Association. Guidelines for the diagnosis and treatment of hyperuricemia and gout in China (2019)[J]. Chin J Endocrinol Metab, 2020, 36(1): 1-13. DOI: 10.3760/cma.j.issn.1000-6699.2020.01.001.
[8]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398. DOI: 10.3760/cma.j.cn311282-20210304-00142. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 Edition)[J]. Chin J Endocrinol Metab, 2021, 37(4): 311-398. DOI: 10.3760/cma.j.cn311282-20210304-00142.
[9]	诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华循环杂志, 2016, 31(10): 937-953. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG202001019.htm Zhu JR, Gao RL, Zhao SP, et al. Guidelines for the prevention and treatment of dyslipidemia in adults in China (2016 Revised Edition)[J]. Chin Circul J, 2016, 31(10): 937-953. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG202001019.htm
[10]	中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002. China Hypertension Prevention and Treatment Guidelines Revision Committee, Chinese Hypertension League, Chinese Society of Cardiology, et al. Guidelines for the prevention and treatment of hypertension in China (2018 Revised Edition)[J]. Chin J Cardiovasc Med, 2019, 24(1): 24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.
[11]	中国心血管病预防指南写作组. 中国心血管病预防指南(2017)[J]. 中华心血管病杂志, 2018, 46(1): 10-25. DOI: 10.3760/cma.j.issn.0253-3758.2018.01.004. Chinese Cardiovascular Disease Prevention Guidelines Writing Group. Guidelines for the prevention of cardiovascular diseases in China (2017)[J]. Chin J Cardiol, 2018, 46(1): 10-25. DOI: 10.3760/cma.j.issn.0253-3758.2018.01.004.
[12]	Zhang L, Wang H. Chronic kidney disease epidemic: cost and health care implications in China[J]. Semin Nephrol, 2009, 29(5): 483-486. DOI: 10.1016/j.semnephrol.2009.06.012.
[13]	Silva FG. The aging kidney: a review - part Ⅱ[J]. Int Urol Nephrol, 2005, 37(2): 419-432. DOI: 10.1007/s11255-004-0874-5.
[14]	Silva FG. The aging kidney: a review - part I[J]. Int Urol Nephrol, 2005, 37(1): 185-205. DOI: 10.1007/s11255-004-0873-6.
[15]	黄清华, 严采馨, 林翠婷, 等. 降尿酸药物对高尿酸血症合并多系统并发症的影响研究进展[J]. 中国医院药学杂志, 2022, 42(9): 957-960. DOI: 10.13286/j.1001-5213.2022.09.17. Huang QH, Yan CX, Lin CT, et al. Research progress on the effect of uric acid-lowering drugs on hyperuricemia complicated with multisystem complications[J]. Chin J Hosp Pharm, 2022, 42(9): 957-960. DOI: 10.13286/j.1001-5213.2022.09.17.
[16]	杨彬, 方亚. 非布司他治疗老年4~5期慢性肾病合并高尿酸血症的临床效果及不良反应观察[J]. 吉林医学, 2022, 43(6): 1564-1566. DOI: 10.3969/j.issn.1004-0412.2022.06.043. Yang B, Fang Y. Clinical effect and adverse reaction observation of febuxostat in the treatment of elderly patients with stage 4-5 chronic kidney disease complicated with hyperuricemia[J]. Jilin Medicine Journal, 2022, 43(6): 1564-1566. DOI: 10.3969/j.issn.1004-0412.2022.06.043.